A therapeutic trial of anti-lymphocytic globulin in acute ulcerative colitis.
The results of the preliminary part of a controlled therapeutic trial of antilymphocytic globulin (ALG) in severe acute ulcerative colitis are presented. 10 patients have been studied in this part of the trial, 5 receiving standard treatment with corticosteroids, and 5 receiving ALG, in a dose of 1 g daily for 5 days, in addition to the standard treatment. No difference has been observed in the clinical course of the patients in the two groups. A continuation of the trial is in progress, using ALG in a larger dose (2 g daily for 5 days).
D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000961:Antilymphocyte Serum / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003093:Colitis, Ulcerative / Q000276:immunology / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000305:Adrenal Cortex Hormones; D000961:Antilymphocyte Serum